TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Avecho Biotechnology Limited ( (AU:AVE) ).
Avecho Biotechnology Limited announced a change in the director’s interest notice, specifically for Dr. Gregory Collier, involving the acquisition of 6,338,595 unquoted options. This change reflects ongoing adjustments in the company’s governance and may influence stakeholder perceptions regarding the company’s strategic direction and leadership stability.
More about Avecho Biotechnology Limited
Avecho Biotechnology Limited is a company that develops and commercializes innovative health products for humans and animals using its proprietary drug delivery system, Tocopheryl Phosphate Mixture (TPM). This system, derived from Vitamin E, enhances the solubility and absorption of drugs and nutrients. Avecho’s leading product is a cannabidiol (CBD) TPM soft-gel capsule, which is currently in Phase III clinical trials for treating insomnia.
Current Market Cap: A$12.69M
Find detailed analytics on AVE stock on TipRanks’ Stock Analysis page.